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The Background



Nationally, over 1.2 million Americans
currently living with HIV




In Vermont:

Nearly 1 in 8 (12.8%) are unaware of their
status

New infections consistently around
50,000 / yr


Men who have Sex with Men (MSM) carry
largest burden



25% of new infections are among youth
(13-24yo), many whom are unaware of
HIV status and can pass virus on to others


Family medicine is perfectly poised to
intervene





Average 11-19 new Dx over past 10
years



Total of 670 HIV positive Vermonters
(more accurately, closer to 800
considering those unaware of status)



56% of newly Dx’ed are in MSM
population

2016 US Federal Budget Request = $31.7
Billion for domestic and int’l HIV efforts


$18.5 billion = healthcare services /
treatment for HIV+ individuals



Only $940 million for domestic HIV
prevention


Unchanged for the past 6 years

The Arrival of PrEP


2012: FDA approval of Truvada
(Emtricitabine-Tenofovir 200mg300mg) for Pre-Exposure
Prophylaxis (“PrEP”)


Drug had long history already for
post-exposure treatment of HIV

Clinical Practice Guidelines were
immediately in place in cities with
high LGBT populations (San
Francisco City Clinic, Group Health
Cooperative Seattle, Fenway
Health Boston, Callen-Lorde /
GMHC in NYC)
 Uptake / awareness elsewhere
remains slow (especially in VT)


In Vermont
Provider comfort / familiarity remains
limited
Latest estimate per Vermont Cares,
excluding Planned Parenthood, UVM
Student Health, or UVM Infectious
Disease, is approximately [how many?]
who have actively prescribed PrEP

In Vermont
Provider comfort / familiarity remains
limited
Latest estimate per Vermont Cares,
excluding Planned Parenthood, UVM
Student Health, or UVM Infectious
Disease, is approximately 9 providers
who have actively prescribed PrEP

UVM COM PHP Project: Lack of Provider Training was
the #1 Identified Barrier

College of Medicine Public Health Project Highlights

How to get the word out about
PrEP?


PCP and community awareness & education



The ID community is well aware of PrEP




2013 national survey of ID physicians demonstrated that 74% supported
the use of PrEP, yet only 9% had actually prescribed it.

HIV-negative, or assumed to be, gay men have no reason to see an
ID specialist. If they’re seeing anyone for healthcare, it’s their PCP.


Within marginalized communities, word spreads quickly about which
providers are open and “safe” to talk to.

Having The Talk: Approach to Clinical Assessment of
the Patient – Sexual HIV Acquisition Risk
Sexual history taking:
- 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit in the past year
- However, many providers don’t ask about (and pts don’t disclose) same-sex behaviors
- CDC suggested questions for risk assessment
- Language unique to MSM: “bottoming” vs. “topping”

*** “Are you and your partner exclusive or open?” ***
- San Francisco State Univ “Gay Couples Study”: found 47% of gay relationships are open, 45%
monogamous, and 8% disagreed about their categorization
- focused on HIV infections rising even among primary male couples

Having The Talk: Approach to Clinical Assessment of
the Patient – Sexual HIV Acquisition Risk


For all sexually active pts:


Consider dx of bacterial STIs in past 6 months as evidence of potential
HIV-exposure sexual activity, therefore, risk



Alcohol use / abuse screening (especially before sexual activity)



Screening for use of non-injection drug use in conjunction with
sexual encounters:


Amyl nitrite (“poppers”) – assoc’d w/ sexual encounter enhancement




Smooth muscle (anal sphincter) relaxation, general vasodilation, and
reflexive tachycardia (sensation of “excitement”)

Stimulants: often popular in the circuit-party scene

CDC Clinical Provider’s Supplement
Note age 18-28

Note receptive anal sex
without condom x1

Either of the above
alone is nearly/
already at threshold
to consider Rx of
PrEP

Other Indications for PrEP Use

Considering the IV drug use epidemic in the state, PrEP should
also be first and foremost in prevention of HIV infection in these
high-risk individuals

Lab Tests and Evaluation


1) HIV antibody test


Confirm HIV (-) status before initiating, and every 3 months (ideally within
the week before refilling Rx)



Accomplish via serum HIV ELISA or rapid POC FDA approved fingerstick
blood test


Do NOT use oral rapid tests in PrEP monitoring due to less sensitivity



Do NOT accept self-reported results or documented anonymous results



If positive HIV antibody: follow normal procedure for confirmatory testing



If acute infection suspected within “window period” before antibody
test would become positive, must defer to HIV RNA test for acute
exposure

Lab Tests and Evaluation


2) Renal Function


Obtain serum Cr and eCrCl




Minimum eCrCl of 60ml/min



Among HIV-infected persons prescribed Truvada-containing regimens,
decreases in renal function (eCrCl) have been documented



Occasional cases of acute renal failure

3) Test for active HVB/HCV infection


MSM and IVDU at increased risk



Tenofovir has activity against HBV, thus if pt stops med, reactivation of
HBV  hepatic damage

Lab Tests and Evaluation


Conduct STI testing at least every 6 months



Importance of site-specific testing (2010 CDC STD guidelines for MSM screening)





Urethral G/C if insertive intercourse in past year



Rectal G/C if receptive intercourse in past year



Pharyngeal G/C if receptive oral sex in past year

Studies have not consistently borne out the idea of “risk-compensation” for
individuals on PrEP (i.e. “PrEP instead of condoms”). Some studies have actually
showed condom use increased long-term for individuals on PrEP




Perhaps due to more frequent/regular STI and HIV screening for individuals on PrEP

Anal Paps?


NY State Dept. of Health recommends for HIV+ patients



CDC/USPSTF/ACS do not recommend



Recommendations? HIV- patients = baseline, q2-3 years

Road to Zero


Campaign whose goal is to achieve zero new HIV infections in
Vermont by 2020


Average of 20 new diagnoses per year (over the past 5 years)



“Vermont is in striking distance of becoming the first state ever to
achieve this goal” – VT Cares



PrEP is front and center



Major limitation?


Currently only 9 providers actively prescribing PrEP



“Insufficient to fully demonstrate the public health impact PrEP can
have”


Peter Jacobsen, Executive Director of VT Cares

Cost Concerns




Truvada is covered by:


VT Medicaid



VT Blue Cross – Blue Shield

Gilead “Advancing Access” Copay Card


https://www.gileadadvancingaccess.com/copay-coupon-card



Covers drug cost


U.S. residents



Available for each valid prescription, no other purchase necessary



Pt cannot be currently receiving other free drug assistance through Gilead
patient assistance programs

HIV risk is not static throughout lifetime –
“seasonality” of risk
Identification of high-risk people might be less helpful than identification of
high-risk moments and the situations that cause them, for example:
- Leaving home
- Becoming an adult
- Coming out as a MSM
- Immigrating to a new city
- Ending a relationship
** Family Medicine again is perfectly poised to intervene **
PROUD study reported that unexpectedly high HIV incidence (9 infections
per 100 person-years) in men who asked for PrEP and who were asked by
clinician to defer starting the medication:
- HIV incidence was 3x expected based on epidemiologic trends
- People at higher risk of HIV infection were more likely to seek PrEP
services, stay in care, and be adherent = the motivation is already there
iPrEx study: Evidence that PrEP is a strong attractor for those entering into a
“season of high exposure to HIV”
- Temporal variation in risk behavior

Provider Handout


Quick consult



To be formalized into the UVM Academic Detailing program



Future Goals:



Academic Detailing



Family Medicine Grand Rounds



eLearning module on LGBT health (to include PrEP) in Frymoyer
project for current and future UVM COM students
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